Samuel Connie Wright

US Patent:

20040071633, Apr 15, 2004

Filed:

Aug 13, 2003

Appl. No.:

10/467760

Inventors:

Samuel Wright - Westfield NJ, US
Tian-Quan Cai - Hillside NJ, US

International Classification:

A61K049/00
G01N033/53

US Classification:

424/009100, 435/007100

Abstract:

This invention provides a method for screening and/or determining the efficacy of known or potential reverse cholesterol transport-enhancing compounds in mammals that avoids the need for measuring cellular protein or mRNA levels and instead employs measurements of CD14 levels in blood.

US Patent:

20040115127, Jun 17, 2004

Filed:

Oct 16, 2003

Appl. No.:

10/475038

Inventors:

Samuel Wright - Westfield NJ, US
Tian-Quan Cai - Edison NJ, US

International Classification:

A61K031/00
A61M036/14
A61K051/00

US Classification:

424/001490, 514/001000

Abstract:

The invention encompasses a method for treating or preventing an inflammatory disease or condition in a mammalian patient in need of such treatment or prevention comprising administering to said patient a compound that is capable of simultaneously binding PPAR and PPAR or concomitantly administering a compound that selectively binds PPAR with a compound that selectively binds PPAR in an amount that is effective to treat or prevent the inflammatory disease or condition. The invention also encompasses a method for treating or preventing an inflammatory disease or condition in a mammalian patient in need of such treatment or prevention comprising administering to said patient a compound that is capable of simultaneously binding and activating PPAR and PPAR or concomitantly administering a compound that selectively binds and activates PPAR with a compound that selectively binds and activates PPAR in an amount that is effective to treat or prevent the inflammatory disease or condition.

US Patent:

20040116327, Jun 17, 2004

Filed:

Oct 16, 2003

Appl. No.:

10/475036

Inventors:

Samuel Wright - Westfield NJ, US
Tian-Quan Cai - Edison NJ, US

International Classification:

A61K031/00

US Classification:

514/001000

Abstract:

The invention encompasses a method for preventing the rupture of atherosclerotic plaques in a mammalian patient in need of such prevention comprising administering to said patient a compound that is capable of simultaneously binding or binding and activating PPAR and PPAR or concomitantly administering a selective PPAR agent with a selective PPAR agent in an amount that is effective to prevent the rupture of atherosclerotic plaques. The invention also encompasses a method for increasing atherosclerotic plaque stability in a mammalian patient in need thereof comprising administering to said patient a compound that is capable of simultaneously binding or binding and activating PPAR and PPAR or concomitantly administering a selective PPAR agent with a selective PPAR agent in an amount that is effective to increase plaque stability.

US Patent:

20040167107, Aug 26, 2004

Filed:

Dec 19, 2003

Appl. No.:

10/482233

Inventors:

Samuel Wright - Westfield NJ, US

International Classification:

A61K031/573

US Classification:

514/171000

Abstract:

The present invention relates to a method for treating or preventing cachexia in a patient in need thereof comprising administering to said patient a PPAR agonist in an amount that is effective to treat or prevent cachexia. Combination therapies and pharmaceutical compositions for treating or preventing cachexia are also encompassed.

US Patent:

20040242459, Dec 2, 2004

Filed:

Dec 9, 2003

Appl. No.:

10/480363

Inventors:

Michael Forrest - Shrewsbury NJ, US
Joel Berger - Hoboken NJ, US
David Moller - Bedminister NJ, US
Samuel Wright - Westfield NJ, US

International Classification:

A61K038/17

US Classification:

514/002000

Abstract:

A method for treating, controlling, preventing or reducing the risk of contracting an inflammatory disease or condition in a mammalian patient, comprises the steps of (1) selecting a patient in need thereof, and (2) treating the patient with a therapeutically effective amount of a composition comprising a PPAR- agonist. Inflammatory diseases that may be treated by this method include but are not limited to rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, degenerative joint disease, one or more connective tissue diseases, ankylosing spondylitis, and bursitis.

US Patent:

20040248863, Dec 9, 2004

Filed:

Dec 19, 2003

Appl. No.:

10/481869

Inventors:

Samuel Wright - Westfield NJ, US

International Classification:

A61K031/573

US Classification:

514/171000

Abstract:

The present invention relates to a method for treating or preventing an inflammatory disease or condition in a patient in need thereof comprising concomitantly administering to said patient a PPAR agonist and a glucocorticoid in amounts that are effective to treat or prevent the inflammatory disease or condition. Pharmaceutical compositions for treating or preventing an inflammatory disease or condition are also encompassed.

US Patent:

20040259850, Dec 23, 2004

Filed:

Apr 30, 2004

Appl. No.:

10/494548

Inventors:

Stephen Alves - New York NY, US
Milton Hammond - Somerville NJ, US
Samuel Wright - Westfield NJ, US

International Classification:

A61K031/56

US Classification:

514/169000

Abstract:

A tachykinin receptor antagonist, in particular a neurokinin-1 receptor antagonist, is useful for the treatment or prevention of hot flashes associated with hormonal variation in a patient.

US Patent:

20130190226, Jul 25, 2013

Filed:

Jun 30, 2011

Appl. No.:

13/805488

Inventors:

Samuel Wright - Westfield NJ, US
Martin Imboden - Munsingen, CH
Reinhard Bolli - Guemlingen, CH
Marcel Waelchli - Gwatt, CH

International Classification:

A61K 38/17

US Classification:

514 19, 514 74

Abstract:

A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.